Xbrane Biopharma and STADA have announced that they have entered into a collaboration agreement for the development of a ranibizumab biosimilar, referencing Lucentis, which will prospectively be sold as Xlucane, in the US, European, and other markets.
Xbrane Biopharma and STADA have announced that they have entered into a collaboration agreement for the development of a ranibizumab biosimilar, referencing Lucentis, which will prospectively be sold as Xlucane, in the US, European, and other markets.
The agreement stipulates that each organization must equally contribute to development expenses and share profits from commercialization of the potential biosimilar in an equal split. Additionally, STADA will make an upfront payment to Xbrane of approximately $8.7 million (€7.5 million).
“The co-development deal with STADA is a significant achievement and opportunity for Xbrane which confirms Xbrane’s unique capabilities and competencies in biosimilar development,” said Anders Tullgren, chairman of the board of directors at Xbrane, in a prepared statement.
Xbrane will be responsible for developing the biosimilar until submissions for regulatory approval are made to the European Medicine’s Agency (EMA) and the FDA. STADA will hold the marketing authorizations and will also be accountable for the sales and marketing of the product across all territories included in the agreement (Europe, the United States, the Middle East and North Africa, and Asia).
The organizations have indicated that they are ready to move forward with the initiation of a phase 1 and phase 3 clinical trial, and say that they have agreed on the study design with both the EMA and FDA. The study will enroll patients with wet age-related macular degeneration across 16 countries.
“The deal will contribute significant funding and expertise for the development and commercialization of Xulcane and will help to accelerate the development of our pipeline of biosimilars, as well as the transformation of Xbrane into a major player in the fast-growing global biosimilars market,” said Tullgren.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.